Alto Neuroscience Investor Relations Material

Alto Neuroscience Inc. is a clinical-stage biopharmaceutical company based in the United States, focusing on developing precision medicine for psychiatric conditions. The company leverages AI-derived brain biomarkers to tailor psychiatric drug development to individual patients, aiming to improve treatment effectiveness for mental health issues. Their approach integrates detailed patient-specific data to optimize the drug development process. Alto Neuroscience has a range of products in clinical trials targeting conditions such as major depressive disorder and post-traumatic stress disorder. The company is headquartered in Los Altos, California, and its shares are listed on the NYSE under the ticker ANRO.